eNewsletter Signup
Miles
Km80.5

Biomarker Scientist –Translational Medicine OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc.

Location: Redwood City, CA Posted Date: 4/19/2013 Position Type: Full time Job Code: #job_2 Required Education: Doctorate/PhD Areas of Expertise Desired: Clinical Data Management
Clinical Research

Description

SUMMARY:
We are looking for a highly motivated senior level Scientist to Director level person to work closely with VP Translational Medicine and other key clinical personnel to ensure that biomarker goals are executed in OncoMed’s clinical trials, with focus on pharmacodynamic and predictive biomarkers.  Provides direct support and leadership, as well as strong individual contribution to managing OncoMed’s clinical biomarker operations including scientific, strategic and logistical aspects.  Collaborates closely with development and research teams.

RESPONSIBILITIES:
• Individual contribution including direct hands-on biomarker assay development and analysis.
• Manage and provide direct hands-on contribution to several aspects of OncoMed’s clinical biomarker operations, including clinical sample tracking and writing laboratory manuals for upcoming trials.
• Develops strategy around the use of Predictive Medicine technologies.
• Writes the appropriate biomarker sections of clinical trial protocols to outline and explain the execution of the strategy.
• Evaluate emerging technologies and vendors to consider for future programs and to interpret data across programs.
• Works within a matrix environment, collaborating with research and clinical teams

Requirements

• Ph.D. with 5-10 years pharmaceutical industry experience.

About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells shown to be capable of driving tumor growth, recurrence and metastasis.  OncoMed has advanced five anti-cancer therapeutics into the clinic, including demcizumab (OMP-21M18, Anti-DLL4), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), OMP-18R5 (Anti-Fzd7), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt.  In addition, OncoMed’s pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways, including the RSPO-LGR pathway.  OncoMed has formed strategic alliances with Bayer Pharma AG and GlaxoSmithKline.  Additional information can be found at the company’s website: www.oncomed.com.


E-Mail to a Friend Add to Job Folder



By applying to/saving a job using , you are agreeing to comply with and be subject to the Terms of Use for use of our website. To use our website, you must agree with the Terms of Use and both meet and comply with their provisions.

ADVERTISEMENTS